We present an overview of clinical trials involving gene editing using clustered interspaced
short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription …

CRISPR-Cas9 is an RNA-mediated adaptive immune system that protects bacteria and
archaea from viruses or plasmids. Herein we discuss the recent development of CRISPR …

CRISPR-associated protein 9 (Cas9)-mediated genome editing provides a promising cure
for HIV-1/AIDS; however, gene delivery efficiency in vivo remains an obstacle to overcome …

Elimination of HIV DNA from infected individuals remains a challenge in medicine. Here, we
demonstrate that intravenous inoculation of SIV-infected macaques, a well-accepted non …

As genome-editing nucleases move toward broader clinical applications, the need to define
the limits of their specificity and efficiency increases. A variety of approaches for nuclease …

HIV-1/AIDS remains a global public health problem. The world health organization (WHO)
reported at the end of 2019 that 38 million people were living with HIV-1 worldwide, of which …

HIV presents one of the highest evolutionary rates ever detected and combination
antiretroviral therapy is needed to overcome the plasticity of the virus population and control …

Gene-editing technology is an emerging therapeutic modality for manipulating the
eukaryotic genome by using target-sequence-specific engineered nucleases. Because of …

ABSTRACT A disease of more than 39.6 million people worldwide, HIV-1 infection has no
curative therapy. To date, one man has achieved a sterile cure, with millions more hoping to …

Human immunodeficiency virus (HIV) infections and HIV-induced acquired
immunodeficiency syndrome (AIDS) continue to represent a global health burden. There is …